Abiomed (ABMD) Misses Q2 EPS by 4c; Maintains Revenue Outlook
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Financial Fact:
Research and development: 18.05M
Today's EPS Names:
ELWT, CAAP, RNW, More
Financial Fact:
Research and development: 18.05M
Today's EPS Names:
ELWT, CAAP, RNW, More
Join SI Premium – FREE
Abiomed (NASDAQ: ABMD) reported Q2 EPS of $0.20, $0.04 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Abiomed maintains FY2017 revenue of $435-445 million, versus the consensus of $446.33 million.
For earnings history and earnings-related data on Abiomed (ABMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
